

**LACHMAN CONSULTANT SERVICES, INC.**  
CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES

1600 STEWART AVENUE, WESTBURY, NY 11590  
(516) 222-6222 • FAX (516) 683-1887

7 1 6 2 1 0 3 0 3 0 1 0 0 0

June 28, 2004

**OVERNIGHT COURIER 6/28/04**

Division of Dockets Management  
Food and Drug Administration (HFA-305)  
Department of Health and Human Services  
5630 Fishers Lane, Room 1061  
Rockville, MD 20852

**Withdrawal of Citizen Petition Docket No. 2004P-0243/CP1**

Dear Sir or Madam:

The above-referenced petition was submitted on May 21, 2004 (received and filed on May 24, 2004), under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, and in accordance with 21 CFR 10.30 on behalf of a client requesting the Commissioner of the Food and Drug Administration to declare that the combination drug product, Oxycodone and Acetaminophen Tablets, USP, in strengths of 2.5 mg / 400 mg, 5 mg / 400 mg, 7.5 mg / 400 mg, and 10 mg / 400 mg, are suitable for submission in an abbreviated new drug application (ANDA). We respectfully request that this petition be considered as withdrawn.

Sincerely,

*Robert W Pollock*  
lu

Robert W. Pollock  
Vice President  
Lachman Consultant Services, Inc.  
1600 Stewart Avenue  
Westbury, NY 11590

RWP/lu

cc: Emily Thakur (Office of Generic Drugs)

A43P4180

2004P-0243

WDL 1